GleamWall
中文EN

IMRN Immuron Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1660046 · Reporting currency AUD · Fiscal year ends 06/30

Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY48.6%
TTM net income YoY24.8%
TTM EPS YoY25.7%
Revenue 3-yr CAGR112.0%
Net income 3-yr CAGR—

Margins

Gross margin65.4%
Operating margin-73.3%
Net margin-71.6%
FCF margin—
EBITDA margin-72.7%

Returns

ROE-50.2%
ROA-40.6%
ROIC (approx.)-134.2%
Asset turnover0.57x

Leverage & solvency

Liabilities / assets20.3%
Debt / equity0.00x
Current ratio5.09x
Interest coverage-731.63x

Cash quality & payout

Operating cash flow / net income1.18x
Accruals ratio7.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: AUD FY20252025-06-30FY20242024-06-30
Income statement
Revenue7.29M4.90M
Cost of revenue2.52M1.57M
Gross profit4.77M3.34M
R&D expense3.60M5.38M
SG&A expense4.48M4.56M
Operating income-5.34M-5.80M
Interest expense7,3057,576
Pretax income-5.22M-6.94M
Net income-5.22M-6.94M
EBITDA-5.29M-5.76M
EPS (basic)-2.26-3.04
EPS (diluted)-2.26-3.04
Weighted avg. shares (diluted)230.94M227.86M
Balance sheet
Cash & equivalents2.83M11.66M
Receivables1.93M1.39M
Inventory1.77M1.58M
Current assets10.02M14.73M
PP&E, netmay include right-of-use assets (IFRS)113,950154,347
Total assets10.13M15.55M
Current liabilities1.97M2.70M
Total liabilities2.06M2.84M
Shareholders' equity8.07M12.71M
Cash flow statement
Operating cash flow-6.14M-5.88M
Capital expenditure—195
Free cash flow—-5.88M
Investing cash flow-2.90M327,561
Financing cash flow199,747829
Depreciation & amortization49,68845,981
Stock-based compensation304,2433,299

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.